Peptides: what is proven, what is hype, what is legal

A peptide is a short chain of amino acids linked by peptide bonds, the same chemistry that builds every protein in your body.^[2] The line between peptide and protein is fuzzy. By the convention of IUPAC, the body that sets chemistry's naming rules, chains of 10 or more amino acids are called polypeptides.^[50] Once a chain folds into a stable three-dimensional shape, usually from around 50 amino acids, most chemists start calling it a protein. Insulin, with 51 amino acids,^[1] sits right on that border and gets called both, which is about as tidy as chemical naming gets.

Whatever you call them, your body uses these chains as messengers. Insulin lowers blood sugar, oxytocin drives labour and bonding, and vasopressin helps your kidneys hold on to water.^[1] GLP-1, released by the gut after a meal, boosts insulin and makes you feel full, which is why Ozempic and Wegovy imitate it.^[1] Ghrelin sends the opposite message and signals hunger.

Why most peptides are injected, not swallowed. The messenger job comes with a short life span: natural GLP-1 is cut apart by an enzyme called DPP-4 within minutes of its release.^[1] Swallow a peptide and the enzymes in your stomach and gut digest it like any other protein, which is why most peptide drugs are injections.^[1] Oral semaglutide (Rybelsus, 2019) gets around this with an absorption enhancer that shields it in the stomach.^[1] Even then only about 1 percent of the dose reaches the blood, but the drug is so potent that this small share is enough.

Rybelsus is not the only peptide pill. Cyclosporine, a ring-shaped peptide, has been sold as an oral drug since 1983. Oral octreotide (Mycapssa, 2020) later followed Rybelsus, again with an absorption enhancer and very low uptake.^[1] These pills are still the exception, though, and most peptide drugs are injected.

Peptide drugs are about a hundred years old, and the first one, injected insulin, is still the most important. Frederick Banting isolated insulin in 1921, and by 1923 it was the first commercial peptide drug.^[1] For decades insulin had to come from animal pancreases, so the next breakthroughs were about making peptides instead of extracting them. Chemists built synthetic oxytocin in the 1950s. In 1963 Bruce Merrifield invented solid-phase peptide synthesis, which grows the chain one amino acid at a time on a tiny polymer bead.^[1] That method still underpins peptide manufacturing today. Living cells became the next factory: by the early 1980s, genetically engineered bacteria were making human insulin (Humulin, approved in the US in 1982).^[1]

Making hormones in bacteria also turned out to be safer than harvesting them. In 1985 doctors linked cases of Creutzfeldt-Jakob disease in young people to growth hormone taken from the pituitary glands of dead donors. Creutzfeldt-Jakob is a fatal brain disease caused by prions (infectious misfolded proteins), so the programme was stopped. Growth hormone made by bacteria (Genentech's Protropin, also 1985) replaced it.

The class that made peptide drugs famous came later, and it started with a lizard. In 1992 John Eng isolated exendin-4 from the venom of the Gila monster, a desert lizard.^{[1, 3]} Exendin-4 became exenatide (Byetta, 2005), the first GLP-1 drug, and showed that a long-lasting drug acting like GLP-1 could treat diabetes.^[3] Later drugs such as liraglutide (Victoza 2010, Saxenda 2014) and semaglutide (Ozempic 2017, Wegovy 2021) were built from human GLP-1 instead.^[1] Tirzepatide (Mounjaro 2022, Zepbound 2023) took a different route. It is built on a second gut hormone, GIP, and acts on the receptors for both GIP and GLP-1.^[82]

The grey market has a different origin. In 1993 Predrag Sikiric's group in Zagreb described BPC-157, a 15-amino-acid peptide said to be a fragment of a "body protection compound" in human gastric juice. Most research on it still comes from that group. Together with a handful of other peptides that never became approved drugs, it forms the core of today's "research peptide" market.

How the US reined in the grey market

The FDA moved against that market on 29 September 2023, when it listed a cluster of grey-market peptides in Category 2 of its interim bulks lists.^[40] Category 2 means the FDA has flagged significant safety risks, so it does not let compounders use these substances while the policy applies.^[40] For 503A pharmacies, which mix drugs to order for individual patients, the listing covered BPC-157, the TB-500 fragment, MOTS-c, KPV, epitalon, Semax, DSIP, GHK-Cu (injectable), Melanotan II, PEG-MGF and LL-37. Ipamorelin, GHRP-2 and GHRP-6 went into Category 2 for 503B outsourcing facilities.^[40] By April 2026 the people who had nominated BPC-157 and 16 other substances had withdrawn those nominations, and the FDA now lists them separately.^[6] That move did not make compounding them lawful.^{[6, 23]}

At the same time the FDA was closing a second door, the one for compounded copies of GLP-1 drugs. It declared the tirzepatide and semaglutide shortages resolved (October 2024, confirmed December 2024, and February 2025). After transition periods that ran until spring 2025, compounders may no longer make routine copies of these drugs. A pharmacy can still compound for one patient if the prescriber documents a significant clinical difference.^[59] Enforcement followed: from September 2025 the FDA sent warning letters to telehealth sellers of compounded GLP-1s, and on 3 March 2026 it announced letters to 30 more companies.^[22]

The peptide question came back on 23 and 24 July 2026, when seven of the grey-market peptides went before the FDA's Pharmacy Compounding Advisory Committee. The committee recommended adding six of them (BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon) to the list of substances 503A pharmacies may use, but not DSIP.^[23] The votes were split, and BPC-157 passed 8 to 6 with one abstention, judged as a treatment for ulcerative colitis.^[41] That vote went ahead even though FDA reviewers had found too little evidence to judge its safety or effectiveness.^{[23, 42]} It is not binding, and until the FDA changes the list through a formal rule, these peptides still cannot be lawfully compounded.^[23]

As of October 2026 the FDA has taken no final action. On 14 October 2026 it sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House regulatory office (OIRA) for review.^[67] Whatever that policy says, none of these peptides is an approved drug in the US or the EU. The US debate is about pharmacy access, not about proof that they work.

Outside the grey market, peptides are ordinary medicine. More than 80 peptide drugs had been approved worldwide by 2022,^[1] and doctors prescribe many of them routinely, from diabetes and obesity to osteoporosis and resistant infections. Grey-market vials are what many people picture when they hear "peptide therapy", yet most of the story has played out in ordinary pharmacies. Most approved peptides copy or tweak one of the body's own hormones, and several antibiotics are peptides too.^[1] The table shows the main areas, with a few well-known examples each.

Source: Wang et al. 2022.^[1]

The newest approvals target much smaller groups of patients. In 2025 the FDA gave elamipretide (Forzinity) accelerated approval to improve muscle strength in Barth syndrome, a rare inherited disease, in patients weighing at least 30 kg.^[60] That is the usual path for a peptide drug: a defined disease, trials in patients who have it, and a label that says who it is for. An approval therefore covers the disease the drug was tested in, not every use people find for it later. None of the peptides in the table is approved to slow ageing.

The peptides sold for longevity are not among the approved drugs, and their evidence is far thinner. This grey-market stack is roughly a dozen injectable peptides (BPC-157, TB-500, sermorelin, ipamorelin, CJC-1295, MOTS-c, epitalon and others) sold by US compounding clinics, telehealth sites and "research peptide" vendors. A few have a narrow registered use somewhere: tesamorelin for HIV-related abdominal fat in the US, thymosin α1 in some countries, and Semax and Selank as nasal drops in Russia. None of them is proven for longevity.^{[24, 46, 47, 77, 78]} The rest range from promising in mice to pure marketing.

BPC-157 and TB-500

BPC-157 is a synthetic 15-amino-acid peptide marketed for joint, tendon and gut healing, and its evidence comes mostly from animals and from one lab. A PubMed search in October 2026 finds about 230 papers on it, and roughly three in four list Sikiric or Seiwerth of the University of Zagreb as an author. Nearly all of that work is preclinical, meaning done in animals or lab dishes. A 2025 review for sports medicine found 35 animal or lab studies and a single human one.^[4]

The human record is thinner still. A 2026 systematic review found only three human studies, with 30 people in total, all of poor quality, and advises against clinical use outside regulated trials.^[44] A few older trials were only ever reported as short conference summaries (meeting abstracts), with too little detail to judge.^[42] So no confirmatory trial, the kind that repeats a result in more people, has shown that BPC-157 works.

Regulators have drawn their own conclusions from that gap. The FDA placed BPC-157 in 503A Category 2 in September 2023, citing possible immune reactions, peptide-related impurities and missing human safety data.^{[6, 40]} The withdrawal of its nomination by April 2026 moved it to a separate list but did not make compounding it lawful.^{[6, 23]} In sport the question is settled, because WADA bans it under S0 (non-approved substances).^{[5, 17]}

TB-500 is often sold as BPC-157's recovery partner, and it is easily confused with a better-studied molecule. It is a synthetic seven-amino-acid fragment of thymosin β4, a natural protein that binds actin, part of the cell's internal scaffolding, and it is marketed for tissue repair. The FDA found no clinical studies of TB-500 in humans.^[45] Phase 2 trials by the company RegeneRx did exist, but they tested full-length thymosin β4, a different molecule. Like BPC-157, TB-500 was placed in FDA 503A Category 2 in 2023, and its nomination was later withdrawn.^{[6, 40]} WADA bans it under S2 (peptide hormones and growth factors).^[17]

Thymosin α1 and tesamorelin: approved, but for narrow uses

Being a real drug somewhere is not the same as being a longevity drug, and these two show the difference. Thymosin α1 (Tα1, Zadaxin) is reported as approved in more than 35 countries, mainly for hepatitis B and C and as an immune booster.^[47] In Italy it is authorised as an add-on to flu vaccination in people with weak immune systems, though the FDA says it cannot verify these approvals itself.^[48] Its largest trial, in 1,106 people with sepsis (a life-threatening overreaction to infection), found no effect on 28-day mortality,^[46] and it is not FDA-approved.

Tesamorelin (Egrifta, Egrifta WR) is a stabilised copy of GHRH, the hormone that tells the pituitary to release growth hormone. The FDA approved it in 2010 for HIV-associated lipodystrophy, a build-up of deep belly fat in some people treated for HIV. Its Phase 3 evidence covers that use only. In Europe the application was withdrawn in 2012 after the EMA's expert committee doubted the benefit was clinically meaningful and flagged rising IGF-1 levels.^[24]

Growth-hormone boosters: sermorelin, ipamorelin, CJC-1295

Tesamorelin's cousins work the same growth-hormone axis with less behind them. Sermorelin, a shortened version of GHRH, was FDA-approved in 1997 as Geref for children with growth-hormone deficiency, after a diagnostic version had been on the market since 1990. Its maker, EMD Serono, discontinued it in 2008, and in 2013 the FDA formally determined that it was not withdrawn for safety or effectiveness reasons.^[13] Since then it has been available in the US only as a compounded drug. Ipamorelin, which acts on the receptor for the hunger hormone ghrelin, was never FDA-approved. It failed a Phase 2 trial in postoperative ileus, a gut that stops moving after surgery. Since September 2023 it has been in FDA Category 2 for 503B outsourcing facilities.^{[6, 40]}

CJC-1295 with DAC is a long-acting GHRH copy (DAC is a chemical add-on that keeps it in the blood for days), and its development ended with a death. ConjuChem's Phase 2 trial in HIV lipodystrophy was stopped in 2006 after a participant died.^[49] According to the FDA's summary, he developed chest pain about two hours after his 11th weekly dose, and an ECG showed a heart attack. He died about an hour later. The treating physician attributed it to undiagnosed coronary artery disease, and the study was ended with its data never published.^[49]

MOTS-c and the rest of the stack

MOTS-c draws the most genuine scientific interest of the unapproved peptides. It is a 16-amino-acid peptide encoded in the DNA of mitochondria, the cell's power plants. The Cohen lab at the University of Southern California described it in 2015.^[73] The mouse data are solid, but there are no human longevity trials. CohBar, which took a related compound (CB4211) into a first trial in people,^[79] announced in November 2023 that it would wind down and dissolve.^[74] Humanin, another mitochondrial peptide first described in 2001, is also mostly preclinical.^[36]

The rest of the stack has even less to show:

• Epitalon (AEDG), a four-amino-acid peptide claimed to lengthen telomeres (the protective caps on chromosomes), comes mostly from one research group in St Petersburg. About two in three of the roughly 170 papers on it in PubMed list Vladimir Khavinson or Vladimir Anisimov as an author (PubMed search, October 2026). Independent replication is very limited, and a 2025 UK study that found longer telomeres in human cell lines says nothing about effects in people.^[63]
• GHK-Cu, a copper peptide, has decent small-trial data as a skin cream, but injected it has no randomised human trials.
• AOD-9604, a growth-hormone fragment, was developed as a weight-loss drug, was never approved, and is sold by clinics without new evidence.
• Selank and Semax are registered in Russia as nasal drops: Selank as a non-prescription anti-anxiety medicine, Semax as a medicine for neurological conditions.^{[77, 78]} Everywhere else they are research chemicals, and no registration covers injecting them for longevity.
• Cerebrolysin, a peptide mix from pig brain, is not FDA-approved. In vascular dementia a Cochrane review calls the evidence weak and industry-funded and says any benefit "may be too small to be clinically meaningful".^[61] In acute stroke the Cochrane review found no effect on death but more than twice as many non-fatal serious adverse events.^[62]

Three of the most popular items, sermorelin, ipamorelin and CJC-1295, share one goal: they raise growth hormone and IGF-1. That goal is exactly what longevity biology calls into question.

Growth-hormone boosters raise a signal whose reduction extends life in worms and mice, while the human findings are mixed, and that clash is the IGF-1 paradox. Sermorelin, ipamorelin, CJC-1295, tesamorelin and the pill MK-677 all push your pituitary to release more growth hormone (GH). GH in turn makes the liver produce more IGF-1 (insulin-like growth factor 1, the signal that carries much of GH's effect). Clinic protocols are designed to raise both, by an amount that depends on the drug and dose.

The animal side of the paradox is one of the best-replicated findings in ageing research. Roundworms (C. elegans) with mutations in daf-2, the worm's version of the insulin/IGF-1 receptor gene, live up to twice as long as normal worms.^[64] Mice point the same way: Ames and Snell dwarf mice, which make very little GH, live substantially longer than normal mice.^{[75, 76]}

The closest human parallel is Laron syndrome, a rare gene defect that disables the GH receptor and leaves IGF-1 very low. In an Ecuadorian group with the condition, followed for more than 22 years, the affected people had almost no diabetes and one non-lethal cancer despite frequent obesity. Their unaffected relatives had 5 percent diabetes and 17 percent cancer.^[9]

In ordinary people the link is less tidy. Among 184 people in their 90s, women with below-median IGF-1 survived longer than those above the median, while men showed no difference.^[10] A larger pooled analysis of 19 cohorts complicates that picture: both low and high IGF-1 were linked to higher mortality than mid-range levels, a U-shaped curve.^[56] Both are observational studies (from watching people, not from experiments), so they show links, not causes.

The high end of that curve has its own disease. Acromegaly, the disease of chronically high GH and IGF-1, goes with more cancer. A 2023 meta-analysis found thyroid cancer at around 7 times and colorectal cancer at about twice the expected rate.^[31] A nationwide Danish study found a smaller rise, though, and warned that older single-centre studies overstate it.^[32]

The cell-level picture adds a second reason for caution. In the 2023 update of the Hallmarks of Aging, a list of the processes researchers see as drivers of ageing, failing autophagy became a hallmark of its own.^[11] Autophagy is your cells' recycling programme for damaged parts. IGF-1 can switch on mTORC1, the cell's main growth switch, which in some settings suppresses that recycling.^[11] Whether GH-axis peptides do this enough in people to matter is not known.

So a healthy adult who injects these GH boosters to raise IGF-1 is pushing on a lever that long-lived animals have turned down. Users report better sleep, a leaner body and faster recovery, but these reports are not well tested. A leaner body on a scan is also not the same as better health. No human trial has shown that GH-axis peptides extend lifespan. Whether raising IGF-1 in healthy adults shortens life is still open, and the animal data and the cancer signal in acromegaly are reasons for caution, not proof.

The risks of grey-market peptides are not theoretical. Falsified products have put people in hospital, and one death after an illegal injection is under investigation.^{[19, 21]} The first problem is what is actually in the vial.

What is in the vial

A 2024 study bought "semaglutide" without a prescription from three online sellers and tested it in the lab.^[7]:

• Purity: 7.7 to 14.4 percent measured purity, against at least 99 percent claimed.
• Endotoxin (bacterial debris that can cause fever and septic shock when injected): found in all three vials, with the highest level pointing to contamination during production.
• Dose: every vial held about 29 to 39 percent more semaglutide than labelled, an overdose risk on top of the purity problem.

Those results have limits. The vials were sterile and held no peptide-like impurities, heavy metals were not tested, and only semaglutide from three sellers was checked, not BPC-157 or other peptides^[7] The paper also does not compare its endotoxin levels with the official limit for injectable drugs. It therefore shows a poorly controlled production process rather than a measured breach of that limit.

Fake versions of approved drugs

Counterfeits of approved GLP-1 drugs are the second documented problem, and they have reached regulated supply chains:

• WHO alert, June 2024: falsified Ozempic batches turned up in the regulated supply chain in Brazil, the UK and the US between October and December 2023, though the alert does not name the substituted ingredient.^[8] Swissmedic later warned that insulin pens had been relabelled as GLP-1 products, causing life-threatening low blood sugar, with several emergencies in Switzerland.^[21]
• MHRA notice, February 2026: five falsified Mounjaro KwikPen 15 mg pens were found at a private pharmacy clinic in Birmingham after dose-knob faults, and the clinic informed the patients concerned.^[20]
• Salford, May 2025: a 53-year-old woman near Manchester received an illegal £20 weight-loss injection from a beautician, reportedly believed to be semaglutide. She was admitted to hospital four days after her last injection and died after two days in intensive care. Police arrested two people, one on suspicion of manslaughter, and the death is under investigation.^[19]

Dosing errors and reported side effects

Even legally compounded copies of GLP-1 drugs have caused harm. By 31 May 2026 the FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide, some requiring hospital care.^[29] Such reports show an association, not proven cause. Dosing is a separate trap. In 2024 the FDA reported patients who drew five to 20 times the intended dose of compounded semaglutide, often with insulin syringes marked in units.^[58]

Risks of the drugs themselves

GH-axis peptides. Water retention, swelling, carpal tunnel syndrome and insulin resistance are known from GH treatment and acromegaly. How often they occur with GH-releasing peptides in healthy people has not been measured. The longer-term worry is the cancer signal seen in acromegaly, the disease of chronically high GH and IGF-1. A trial of the GH-releasing pill MK-677 (ibutamoren) in older adults recovering from a hip fracture was stopped early because of a heart-failure signal (6.5 percent versus 1.7 percent on placebo).^[27]

BPC-157, TB-500 and blood-vessel growth. In animal and cell studies, BPC-157 stimulates angiogenesis, the growth of new blood vessels.^[4] In lab tests, the seven-amino-acid stretch of thymosin β4 that TB-500 is built on drove blood-vessel sprouting too.^[80] Growing tumours also depend on new blood vessels.^[81] Human cancer data do not exist either way, so the concern rests on the mechanism. But feeding blood-vessel growth is the last thing you want if a tumour you do not know about is already there.

Approved GLP-1 drugs. Even the approved versions carry real risks. A small, single-centre observational study from 2024 linked semaglutide to a higher risk of NAION (non-arteritic anterior ischaemic optic neuropathy, a rare cause of sudden vision loss).^[14] In June 2025 the EMA's safety committee (PRAC) concluded that NAION is a very rare side effect of semaglutide. Studies point to about double the risk, and it may affect up to 1 in 10,000 users.^[30] Across 76 trials, GLP-1 drugs were also linked to about a third more gallbladder and bile-duct disease. The risk was more than twice as high in trials run for weight loss, and higher doses carried more risk.^[57] Because GLP-1 drugs slow stomach emptying, food can still be in the stomach during anaesthesia. If you are having surgery or sedation, tell the anaesthesia team you take one. If your vision suddenly gets worse, get seen urgently.

Why the risk is so hard to pin down

Part of the danger is that nobody can measure it well. Many peptides clear the blood fast and are broken down into ordinary amino acids. So pharmacokinetic studies, which track where a drug goes and how the body clears it, need special methods, and for grey-market peptides they mostly have not been done. Immunogenicity, your immune system making antibodies against the peptide, is one of the FDA's stated concerns.^[6] It can vary from batch to batch and becomes dangerous if the antibodies also attack your body's own version of the hormone. Modified peptides with chemical add-ons such as DAC or PEG have no established reference standards, the pure samples a lab compares a product against. That leaves the person injecting them as the safety study, without the monitoring a real trial would provide.

Who should not use them

No one should inject unapproved peptides outside a regulated trial.^[44] That matters most if you have or have had cancer, for two reasons that are extrapolations rather than findings in people. GH-axis peptides raise growth signals that, in the chronic excess of acromegaly, go with more cancer.^[31] BPC-157 and TB-500 drive blood-vessel growth in lab and animal studies, and tumours need that growth too.^{[4, 80, 81]} The same goes if you are pregnant or breastfeeding, or under 18, since there are no human safety data at all.^{[44, 45]} If you compete in tested sport, BPC-157, TB-500 and GH secretagogues are banned.^[17] For approved GLP-1 drugs, the package leaflet and your doctor say who should not take them.

Germany, Austria and Switzerland treat injectable peptides sold for use in people as medicines, not supplements, so drug law applies to them. Whether a product counts as a medicine is decided product by product: collagen peptides in food or peptides in a face cream are not medicines.^[55] For the injectable kind, the legal route in all three countries is an approved product, a doctor's prescription and a pharmacy. (The same medicines logic covers compounds you swallow, which the NMN Germany guide and the rapamycin Germany guide work through.)

The table shows, for the peptides people ask about most, where each stands and which legal route exists.

Peptide legal status at a glance (as of October 2026):

Sources: EMA^[24] AMG,^[15] FDA,^{[6, 40]} advisory committee reports.^{[23, 41]}

Germany

In Germany the relevant law is the Arzneimittelgesetz (AMG), the medicines act, and its import rule is the one most buyers trip over.

• Import ban (§ 73 AMG): medicines that need an authorisation and do not have one in Germany may not be brought into Germany, by post or otherwise, from inside or outside the EU.^[15] The few exceptions are listed under the legal routes below.
• Ordering for yourself is mainly an administrative offence. Customs seizes the parcel, and you can be fined (§ 97 Abs. 2 Nr. 8 AMG).^[51]
• Selling or passing the product on is a crime,^[34] and so is importing a falsified medicine (§ 96 Nr. 18e AMG).^[34] Selling an unauthorised medicine carries up to 1 year in prison or a fine under § 96 Nr. 5.^[34]
• More serious cases (§ 95 AMG): if the product counts as unsafe (bedenklich, § 5) or is prescription-only and traded outside a pharmacy (§ 43), the penalty rises to up to 3 years, and to 1 to 10 years in especially serious cases such as endangering many people or large-scale profit.^[35]
• Heilpraktiker (licensed non-medical practitioners) may not prescribe prescription-only medicines; only doctors, dentists and vets can (§ 48 AMG).^[69] A Heilpraktiker offering injections of unauthorised peptides still runs into the AMG rules on unauthorised medicines.

The Anti-Doping-Gesetz (AntiDopG) matters even if you never compete, because its two kinds of offence reach different people.^[33] Making, dealing in or supplying a doping agent, and possessing more than a set threshold of a listed substance for doping in sport, are offences for everyone. Using a doping agent on yourself, or holding small amounts for self-doping, is an offence only for elite athletes in a testing pool or for people earning substantial income from sport (§ 4 Abs. 7).^[33]

Those possession thresholds are set in the Dopingmittel-Mengen-Verordnung and apply to substances in the AntiDopG's domestic annex.^{[16, 37]} For the peptide classes sold on the grey market they are:

Source: Dopingmittel-Mengen-Verordnung.^[16]

The 1.5 mg threshold for GHRPs is low enough that a single vial can exceed it. Vials of CJC-1295 or ipamorelin usually hold only a few milligrams, but a stockpile can cross the line. TB-500 and AOD-9604 are both in the annex.^[37]

BPC-157 is not in the AntiDopG's own annex as of October 2026, so possessing it is not caught by the quantity rule (§ 2 Abs. 3).^[37] Making, dealing in, prescribing or giving it to someone else for doping in sport, and self-doping by elite athletes, can still be offences.^{[17, 52, 53]} Those rules use the international anti-doping list, where BPC-157 is banned under S0. Outside sport, the AMG is what applies.

Austria

Austria is stricter about orders than about luggage. Under the Arzneiwareneinfuhrgesetz 2010 (AWEG), Austria's law on importing medicines, travellers may bring medicines for their own personal need (§ 11). If you live in Austria and bought them abroad, that generally means at most three retail packs per medicine.^[54] Ordering medicines by post or online as a private person is banned (§ 17). The one exception is non-prescription medicines authorised in Austria, from a mail-order pharmacy in the EEA.^[54] Illegal parcels are sent back or destroyed at your cost,^[54] so a peptide order to Austria is never legal.

Switzerland

Switzerland is not in the EU and allows small personal imports. Under the Heilmittelgesetz (HMG), the Swiss medicines law, private individuals may import medicines for their own use, including by post. The limit is one month's supply for therapy, and importing for other people is not allowed.^[26] Doping substances follow separate, generally zero-tolerance rules.^[26] Parcels that break these rules are held by customs, and the recipient pays the authorities' costs, at least CHF 540 as of October 2026.^[26]

Those rules are enforced, and peptides classed as doping agents are handled by Swiss Sport Integrity. In a June 2026 customs action, 23 of 46 peptide parcels were held back, 21 of them as doping agents. The other 23 had to be released because the amounts were within legal limits.^[25] Swissmedic sent those recipients a warning that the products are not authorised in Switzerland and that they use them at their own risk.^[25] A tolerated personal import, then, is not an approval. In August 2025 Swissmedic also warned about falsified and misleading GLP-1 weight-loss products, naming an unauthorised "retatrutide injection kit" of unknown quality.^[21]

What is actually legal in DACH

These legal routes exist; some apply only in one country:

1. All three countries: buying a peptide authorised in the country where you buy it (EU or national authorisation in Germany and Austria, Swissmedic authorisation in Switzerland), for example Ozempic, Wegovy or Mounjaro, at a pharmacy with a doctor's prescription.^{[15, 26]} Statutory health insurance in Germany does not pay for drugs used mainly for weight loss (§ 34 SGB V), so Wegovy or Mounjaro for weight management are paid privately (as of October 2026).^[65]
2. Germany: having a pharmacy import a medicine that is legally sold in the country it comes from, such as tesamorelin, for one patient, when a doctor prescribes it for a medical reason and no comparable German medicine exists (§ 73 Abs. 3 AMG).^[15] For tesamorelin that can mean HIV-related abdominal fat, but it is not a route for longevity use, and it never works for BPC-157, which is approved nowhere.
3. Germany: ordering from an EU/EEA mail-order pharmacy in a country on the German Health Ministry's (BMG) published list of states with comparable safety standards, with a valid prescription, for a medicine authorised in Germany.^[15]
4. All three countries: carrying your normal personal supply when you travel.^{[15, 54]} In Germany this covers medicines you carry personally in your luggage when you enter the country, not postal orders (§ 73 Abs. 2 Nr. 6 AMG); in Austria, residents may generally bring at most three packs per medicine bought abroad.^[54]; in Switzerland the limit is one month's therapy, which may also come by post^[26]
5. Germany: a pharmacy-made preparation (Rezeptur, a medicine mixed for one patient) on a doctor's prescription, only if a pharmaceutical-grade substance is available and the doctor sees a medical reason; the pharmacy decides whether it can legally make it. This route does not exist for BPC-157, TB-500 and similar research peptides.

Three common misconceptions

• "BPC-157 is legal in Germany because it is not in the BtMG (the narcotics law)." False. Liability for selling it comes from the AMG (§ 96 Nr. 5, and § 95 in more serious cases), not from the narcotics law.^{[34, 35]}
• "The anti-doping law never applies to me, I'm not a competitive athlete." Partly false. Making, dealing and possessing more than the threshold for doping in sport are offences for everyone; only self-doping and small amounts for your own use are limited to elite athletes.^[33]
• "Mail-order from any EU pharmacy is fine." False. A pharmacy may only send you a medicine that is authorised in Germany, from a country on the BMG list. The only other route is a medicine legal in its EU country of origin, for your personal need, ordered without any commercial middleman (§ 73 Abs. 2 Nr. 6a AMG).^[15]; that never covers BPC-157 and similar products, which are legal nowhere.

For research peptides that are approved nowhere, Germany and Austria offer no legal way to order them. Switzerland at most tolerates a one-month personal import that is not classed as doping, at your own risk^{[25, 26, 54]}

The part of the peptide field that moves fastest is the one with approved drugs behind it. The GLP-1 family has the strongest evidence on hard outcomes, such as heart attacks and deaths, of any new metabolic drug class.^[28] Its newest members push weight loss further still, with retatrutide leading to 25 percent weight loss in the TRIUMPH-1 trial.^[66] Pure-longevity peptides such as MOTS-c and FOXO4-DRI, by contrast, are still preclinical, with minimal human data.

The next GLP-1 drugs

Four drugs show where the GLP-1 family is heading. Retatrutide (Lilly), sold on the grey market as "GLP-3", acts on three hormone receptors at once: GLP-1, GIP and glucagon. CagriSema (Novo Nordisk) pairs semaglutide with cagrilintide, a copy of the hormone amylin, while survodutide (Boehringer Ingelheim and Zealand) acts on the GLP-1 and glucagon receptors. Orforglipron (Lilly) is a pill and not a peptide at all, but a small conventional drug molecule that switches on the GLP-1 receptor. The table compares their main trials, which ran for different lengths and in different groups, so the rows are not a head-to-head ranking.

Sources: TRIUMPH-1,^[66] REDEFINE-1,^[68] survodutide trial,^[70] ATTAIN-1.^[72]

Retatrutide's trial also showed less knee-osteoarthritis pain and sleep apnoea.^[66] Lilly plans to file with the FDA in the first quarter of 2027, so it is approved nowhere yet,^[39] and its long-term safety is not yet known. Orforglipron is already on the market. The FDA approved it as Foundayo on 1 April 2026, the first non-peptide GLP-1 pill for weight loss.^[71] It led to less weight loss than the strongest injectables, though.^[72]

None of these trials measures ageing itself; they measure weight, blood sugar and heart, kidney or liver outcomes. The clearest hard-outcome result so far comes from semaglutide. In the SELECT trial it lowered the combined risk of heart attack, stroke or cardiovascular death by 20 percent. Everyone in that trial had heart disease and overweight or obesity, but no diabetes.^[28] Whether that adds healthy years at the end of life (what researchers call compressed morbidity) is a hypothesis, not yet shown.

The longevity peptides are far behind

The peptides marketed for longevity itself are years behind the GLP-1 drugs. Two lines of research have a credible mechanism. One works with peptides made by mitochondria, the cell's power plants, such as MOTS-c and humanin.^[36] The other aims at senescent cells, old cells that have stopped dividing but do not die. A senolytic peptide (one that kills such cells) called FOXO4-DRI selectively killed them in aged mice.^[12] MOTS-c lost its industrial sponsor when CohBar decided to wind down in 2023.^[74] Nine years after the FOXO4-DRI mouse study, no clinical trial of it is registered (ClinicalTrials.gov search, October 2026). Most other peptides sold for longevity fall into three groups. They work against established ageing biology (the GH-axis boosters), depend on a single research group (BPC-157, epitalon), or are sold for cosmetic and recovery effects relabelled as life extension.

Testing any of them for longevity would take years of follow-up, which is why blood-based ageing clocks draw interest as a possible shortcut for trials. Organ-specific proteomic ageing clocks read blood proteins from UK Biobank participants to estimate how old each of 11 organs looks. In that observational data, an "old" brain or immune system was linked to later disease and earlier death.^[18] Researchers propose using such clocks as faster trial endpoints, but whether a change in a clock means a change in health has not been shown. Until it has, the useful test for any peptide stays the slow one. Before you weigh a peptide, it is reasonable to check whether it is approved for what you want it for, and whether a trial in people backs that use.